NTCD-M3 Emerging Drug Insight and Market Forecast - 2032

This “NTCD-M3 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about NTCD-M3 for clostridium difficile infection (CDI) in the seven major markets. A detailed picture of the NTCD-M3 for clostridium difficile infection in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the NTCD-M3 for clostridium difficile infection. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the NTCD-M3 market forecast analysis for clostridium difficile infection in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in clostridium difficile infection.

Drug Summary

NTCD-M3 (a non-toxigenic strain of C. difficile bacteria- strain M3), previously known as VP 20621, is being developed by Destiny Pharma for the prevention of rCDI. It is an oral formulation of NTCD-M3 spores.

C. difficile NTCD-M3 is a naturally occurring non-toxigenic strain of C. difficile bacteria, which lacks the genes that can express C. difficile toxins. NTCD-M3 temporarily colonizes the human gut without causing any symptoms and the gut microbiome returns to normal a few weeks after treatment. Therefore, it acts as a safe ground cover and prevents the toxic strains of C. difficile from proliferating in the colon after antibiotic treatment.

Phase IIb trials for NTCD-M3 were completed by the Shire and the results were statistically significant confirming efficacy. Destiny Pharma plans to start the Phase III trial by mid of 2023, the design for which was approved by the US FDA in July 2020.

Destiny Pharma is also conducting partnership discussions to co-fund the planned Phase III clinical studies and the subsequent commercialization. It has also received positive scientific advice from EMA on the proposed Phase III study design.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the NTCD-M3 description, mechanism of action, dosage and administration, research and development activities in clostridium difficile infection.
• Elaborated details on NTCD-M3 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the NTCD-M3 research and development activities in clostridium difficile infection across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around NTCD-M3.
• The report contains forecasted sales of NTCD-M3 for clostridium difficile infection till 2032.
• Comprehensive coverage of the late-stage emerging therapies for clostridium difficile infection.
• The report also features the SWOT analysis with analyst views for NTCD-M3 in clostridium difficile infection.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

NTCD-M3 Analytical Perspective

In-depth NTCD-M3 Market Assessment

This report provides a detailed market assessment of NTCD-M3 for clostridium difficile infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

NTCD-M3 Clinical Assessment

The report provides the clinical trials information of NTCD-M3 for clostridium difficile infection covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for clostridium difficile infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence NTCD-M3 dominance.
• Other emerging products for clostridium difficile infection are expected to give tough market competition to NTCD-M3 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of NTCD-M3 in clostridium difficile infection.
• This in-depth analysis of the forecasted sales data of NTCD-M3 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the NTCD-M3 in clostridium difficile infection.

Key Questions

• What is the product type, route of administration and mechanism of action of NTCD-M3?
• What is the clinical trial status of the study related to NTCD-M3 in clostridium difficile infection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the NTCD-M3 development?
• What are the key designations that have been granted to NTCD-M3 for clostridium difficile infection?
• What is the forecasted market scenario of NTCD-M3 for clostridium difficile infection?
• What are the forecasted sales of NTCD-M3 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to NTCD-M3 for clostridium difficile infection?
• Which are the late-stage emerging therapies under development for the treatment of clostridium difficile infection?

This product will be delivered within 2 business days.